Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | IDH1 | O75874 | 1/20 | 0.33 |
| ▸ | NT5E | P21589 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.30 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.30 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.30 |
| ▸ | MEF2D | Q14814 | 1/20 | 0.30 |
| ▸ | GRM5 | P41594 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31568068 | 0.81 | IDH1 (0.36) | LMNAIDH1KDM4E | |
| SCHEMBL24917699 | 0.76 | — | — | |
| SCHEMBL3163858 | 0.75 | CCR4 (0.44) | MEN1KMT2ALMNAKDM4E | |
| SCHEMBL6266188 | 0.75 | MEN1 (0.35) | MEN1KMT2ALMNAIDH1FFAR2 | |
| SCHEMBL6137289 | 0.75 | IDH1 (0.36) | MEN1KMT2ALMNAIDH1FFAR2 | |
| SCHEMBL24917625 | 0.74 | HDAC3 (0.35) | KDM4EHDAC4 | |
| SCHEMBL245790 | 0.73 | SMN1; SMN2 (0.44) | MEN1KMT2ALMNAKDM4EHSP90AA1 | |
| SCHEMBL23642449 | 0.73 | MEN1 (0.34) | MEN1KMT2ALMNAIDH1KDM4E | |
| SCHEMBL3159540 | 0.73 | IDH1 (0.39) | MEN1KMT2ALMNAIDH1NT5E | |
| SCHEMBL7020013 | 0.73 | TRPV4 (0.37) | MEN1KMT2ALMNAIDH1FFAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 256 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12612380-B2 | Non-lysosomal glucosylceramidase inhibitors and uses thereof | ALECTOS THERAPEUTICS 1NC (CA) | 2026-04-28 | — | — | US | disclosed |
| EP-3966199-B1 | NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF | ALECTOS THERAPEUTICS INC (CA) | 2026-03-18 | — | — | EP | disclosed |
| US-12528773-B2 | Non-lysosomal glucosylceramidase inhibitors and uses thereof | ALECTOS THERAPEUTICS INC. (CA) | 2026-01-20 | — | — | US | disclosed |
| US-20260014146-A1 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CEDILLA THERAPEUTICS INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-20250333405-A1 | ANTAGONISTS OF GPR39 PROTEIN | VASOCARDEA INC (US) | 2025-10-30 | — | — | US | disclosed |
| EP-4631938-A1 | NITROGEN-CONTAINING HETEROCYCLE WITH SEROTONIN RECEPTOR-BINDING ACTIVITY AND CARBOCYCLIC DERIVATIVE | Shionogi & Co., Ltd (JP) | 2025-10-15 | — | — | EP | disclosed |
| US-12435061-B2 | Compounds and compositions for use in treating skin disorders | KAMARI PHARMA LTD. (IL) | 2025-10-07 | — | — | US | disclosed |
| US-12410210-B2 | Neuroactive steroids and their methods of use | SAGE THERAPEUTICS, INC. (US) | 2025-09-09 | — | — | US | disclosed |
| EP-4574822-A2 | COMPOUNDS AND COMPOSITIONS FOR USE IN TREATING SKIN DISORDERS | Kamari Pharma Ltd. (IL) | 2025-06-25 | — | — | EP | disclosed |
| EP-4562014-A2 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | Cedilla Therapeutics, Inc. (US) | 2025-06-04 | — | — | EP | disclosed |
| EP-2264009-A1 | PYRIDYLAMINOACETIC ACID COMPOUND | Ube Industries, Ltd. (JP) | 2010-12-22 | — | — | EP | disclosed |
| US-20090192122-A2 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2009-07-30 | — | — | US | disclosed |
| US-7528151-B2 | Heterocyclic urea derivatives for the treatment of pain | GLAXO GROUP LIMITED (GB) | 2009-05-05 | — | — | US | disclosed |
| US-20080249071-A1 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) | 2008-10-09 | — | — | US | disclosed |
| US-20070173537-A1 | Indazole compound and pharmaceutical use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2007-07-26 | — | — | US | disclosed |
| US-20070117820-A1 | Heterocyclic urea derivatives for the treatment of pain | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-05-24 | — | — | US | disclosed |
| EP-1714961-A1 | INDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2006-10-25 | — | — | EP | disclosed |
| EP-1603899-A1 | HETEROCYCLIC UREA DERIVATIVES FOR THE TREATMENT OF PAIN | GLAXO GROUP LIMITED (GB) | 2005-12-14 | — | — | EP | disclosed |
| WO-2004078749-A1 | HETEROCYCLIC UREA DERIVATIVES FOR THE TREATMENT OF PAIN | GLAXO GROUP LIMITED (GB) | 2004-09-16 | — | — | WO | disclosed |
| WO-2004024710-A1 | UREA COMPOUNDS ACTIVE AS VANILLOID RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PAIN | GLAXO GROUP LIMITED (GB) | 2004-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070117820-A1 | Heterocyclic urea derivatives for the treatment of pain | U2SURP, UMPS, SFPQ | MEN1 3230/4885KMT2A 2859/4885LMNA 2076/4885 |
| US-12435061-B2 | Compounds and compositions for use in treating skin disorders | RDX, HAX1, F12 | MEN1 3662/4885KMT2A 1859/4885LMNA 304/4885 |
| US-12528773-B2 | Non-lysosomal glucosylceramidase inhibitors and uses thereof | GBA1, GBA2, GAA | MEN1 3839/4885KMT2A 2598/4885LMNA 2782/4885 |
| US-12410210-B2 | Neuroactive steroids and their methods of use | NR3C2, MC2R, NR3C1 | MEN1 558/4885KMT2A 1347/4885LMNA 1307/4885 |
| US-20070173537-A1 | Indazole compound and pharmaceutical use thereof | CYP3A5, CYP3A43, TP53 | MEN1 1953/4885KMT2A 1257/4885LMNA 3390/4885 |
| US-20090192122-A2 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | IL1B, NFKBIA, IL1A | MEN1 4504/4885KMT2A 4531/4885LMNA 3899/4885 |
| US-20080249071-A1 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | IL1B, NFKBIA, IL1A | MEN1 4504/4885KMT2A 4531/4885LMNA 3899/4885 |
| US-12612380-B2 | Non-lysosomal glucosylceramidase inhibitors and uses thereof | GBA1, GBA2, MAN2B1 | MEN1 3585/4885KMT2A 1488/4885LMNA 1675/4885 |
| US-20250333405-A1 | ANTAGONISTS OF GPR39 PROTEIN | GPR39, GPR139, GPR119 | MEN1 3377/4885KMT2A 4013/4885LMNA 4511/4885 |
| US-20260014146-A1 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CDK2, CDK20, CDK1 | MEN1 3440/4885KMT2A 740/4885LMNA 1379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.